PDAC patients normally have altered tumor suppressor phosphatase and tensin homolog (PTEN) and low expression of PTEN may promote PDAC progression.[165, 166] Katherine et al. discovered GEM treated CAFs could release PTEN targeting miRNAs (miR-21, miR-181a, miR-221, miR-222, and miR-92a) and the suppression of CAF-derived sEV secretion with inhibitor GW4869 could reduce these PTEN targeting miRNAs and restore the PTEN expression.[143] However, these strategies involve the inhibition of sEVs being secreted from both healthy cells and cancer cells. Here, PTEN is linked to cancer.